What do LS RIs offer the life science community?

The 13 European Life Science Research Infrastructures (LS RIs) have the mission to support cutting-edge science by offering access to their resources and services to European scientists from academia and industry.

Resources and services can simply be consultation, access to experts, but also access to data and biological samples, use of data analysis tools, access to facilities (e.g. highly specialised microscopes) plus support from technicians and much more.

Some of these services are even free to use for institutions location in the RI's member states. 

 

The Catalogue of Services, which has been developed within the CORBEL project, is the first tool to list the main services of all LS RIs at a glance and it aims to facilitate the utilisation of RI services by researchers from all over the world. The Catalogue of Services as displayed below aims to provide you a basic overview on existing services within distinct thematic fields.

 

You can either use the Catalogue of Services to identify a single RI to help you with your work or you can create a service pipeline, i.e. using several RIs simultaneously.

What’s your need?

Please select…

ERINHA

Contact person(s): Diana Stepanyan-Yerdamian, Dylan Bonfils, contact(at)erinha.eu

ERINHA is a pan-European distributed life sciences research Infrastructure dedicated to the study of highly infectious emerging and re-emerging high-consequence pathogens (RG4 & unknown). It brings together leading European high containment and complementary research facilities and expertise required to perform cutting-edge research on highly infectious diseases. ERINHA provides access to its state of art BSL-4 laboratories and complementary capacities and expertise to perform excellence orientated in-vitro and in-vivo research projects, trainings and advise. A wide range of capabilities and functions from high basic research laboratory capacities to NHP modeling research are provided by ERINHA, as well as expertise of senior scientists and access to complementary functions (from BSL1 to BSL4, genomics, proteomics etc.).

 

ERINHA produces the ideal environment to facilitate coordination of research on high-consequence pathogens in Europe. The infrastructure will contribute to the enhancement of the European and global capacity, capability and emergency preparedness in the response to global outbreaks.

 

Since 2018, ERINHA has been granted landmark status by the European Strategy Forum on Research Infrastructures (ESFRI).

 

Services provided

The services offered by ERINHA include

  • Access to state of art European high containment (BSL4 & BSL3) and complementary facilities to advance research on high-consequence pathogens. In-vivo testing with a variety of animal models (including small rodents, ferrets, and non-human primates). In-vitro experiments using highly pathogenic agents with both in-person and remote access possibilities.
  • Project coordination and management of large scale research programmes on high consequence pathogens
  • Training (General Biosecurity Training; Operations of a Biosafety Laboratory; Training for potential users)
  • Advice and scientific expertise provider: RG4 pathogens research, containment facilities construction, biosafety/biosecurity issues, sample transport etc.
  • Access to pathogens specimens

Costs

For access costs information contact ERINHA Central Coordinating Unit (CCU) at contact(at)erinha.eu

Access modes

ERINHA provides in-person and remote access to its services. Projects can be submitted by academic, public and industrial users. For more information contact ERINHA CCU at contact(at)erinha.eu

Why work with us

The 2014-2015 Ebola outbreak and cases in Europe demonstrated the worldwide vulnerability and need for common action putting together rare high containment capacities and expertise to be able to increase European and global preparedness for outbreaks of high consequence pathogens. ERINHA facilitates access to required infrastructure capacities thanks to its CCU and multiple high containment and complementary European resources. It is a unique coordinated infrastrucuture providing transnational access to its facilities, large scope of services and shorter delays in access.

Countries involved

Austria (Medical University of Graz), Belgium (KUL), France (Inserm), Hungary (Ministry of Human Capacities), Netherlands (ERASMUS MC), Portugal (INSA), Spain (Instituto de Salud Carlos III), Sweden (FOHM)

Services contact

Contact person(s): Diana Stepanyan-Yerdamian, Dylan Bonfils, contact(at)erinha.eu

About

ERINHA is a pan-European distributed life sciences research Infrastructure dedicated to the study of highly infectious emerging and re-emerging high-consequence pathogens (RG4 & unknown). It brings together leading European high containment and complementary research facilities and expertise required to perform cutting-edge research on highly infectious diseases. ERINHA provides access to its state of art BSL-4 laboratories and complementary capacities and expertise to perform excellence orientated in-vitro and in-vivo research projects, trainings and advise. A wide range of capabilities and functions from high basic research laboratory capacities to NHP modeling research are provided by ERINHA, as well as expertise of senior scientists and access to complementary functions (from BSL1 to BSL4, genomics, proteomics etc.). 

ERINHA produces the ideal environment to facilitate coordination of research on high-consequence pathogens in Europe. The infrastructure will contribute to the enhancement of the European and global capacity, capability and emergency preparedness in the response to global outbreaks.

Since 2018, ERINHA has been granted landmark status by the European Strategy Forum on Research Infrastructures (ESFRI).

General contact

Website: www.erinha.eu

Contact person(s): contact(at)erinha.eu

Please note: Most of the RIs are constantly developing their portfolio of services, so if you do not find the service/tool you are looking for, do not hesitate to contact the RI and ask for it!

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 654248 and from the European Union’s Horizon 2020 programme under grant agreement number 824087.